Literature DB >> 23024707

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.

Bilal Chughtai1, Dean S Elterman, Richard Lee, Alexis E Te, Steven A Kaplan.   

Abstract

Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs - α-adrenergic blockers and 5α-reductase inhibitors - are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.

Entities:  

Keywords:  5α reductase inhibitor; CombAT trial; benign prostatic hyperplasia; combination therapy benign prostatic hyperplasia; dutasteride; fixed-dose benign prostatic hyperplasia; lower urinary tract symptoms; tamsulosin; α-adrenergic blocker

Year:  2012        PMID: 23024707      PMCID: PMC3441136          DOI: 10.1177/1756287212457115

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  30 in total

Review 1.  Pharmacology of lower urinary tract smooth muscles and penile erectile tissues.

Authors:  K E Anderson
Journal:  Pharmacol Rev       Date:  1993-09       Impact factor: 25.468

Review 2.  Clinical and experimental studies of benign prostatic hyperplasia.

Authors:  D S Coffey; P C Walsh
Journal:  Urol Clin North Am       Date:  1990-08       Impact factor: 2.241

Review 3.  Benign prostatic hyperplasia.

Authors:  A Thorpe; D Neal
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

Review 4.  Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists.

Authors:  Shirin Milani; Bob Djavan
Journal:  BJU Int       Date:  2005-06       Impact factor: 5.588

5.  A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.

Authors:  R S Kirby
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

6.  Evaluation and treatment of lower urinary tract symptoms in older men.

Authors:  P Abrams; C Chapple; S Khoury; C Roehrborn; J de la Rosette
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

7.  Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

Authors:  Claus G Roehrborn; Olavi Lukkarinen; Stephen Mark; Paul Siami; Joe Ramsdell; Norman Zinner
Journal:  BJU Int       Date:  2005-09       Impact factor: 5.588

8.  Saw palmetto for benign prostatic hyperplasia.

Authors:  Stephen Bent; Christopher Kane; Katsuto Shinohara; John Neuhaus; Esther S Hudes; Harley Goldberg; Andrew L Avins
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

9.  Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.

Authors:  J Y Gillenwater; R L Conn; S G Chrysant; J Roy; M Gaffney; K Ice; N Dias
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

10.  Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.

Authors:  H Lepor; E Shapiro
Journal:  J Urol       Date:  1984-12       Impact factor: 7.450

View more
  2 in total

Review 1.  Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.

Authors:  Konstantinos Dimitropoulos; Stavros Gravas
Journal:  Ther Adv Urol       Date:  2016-02

Review 2.  New therapeutic strategies for the treatment of male lower urinary tract symptoms.

Authors:  Konstantinos Dimitropoulos; Stavros Gravas
Journal:  Res Rep Urol       Date:  2016-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.